Guided Therapeutics Inc. (OTCMKTS:GTHP – Get Free Report) was the recipient of a significant decline in short interest in June. As of June 30th, there was short interest totaling 19,653 shares, a decline of 39.5% from the June 15th total of 32,466 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 17,349 shares, the short-interest ratio is currently 1.1 days.
Guided Therapeutics Stock Performance
Shares of Guided Therapeutics stock opened at $0.28 on Friday. Guided Therapeutics has a 12-month low of $0.12 and a 12-month high of $0.54. The stock has a market cap of $27.02 million, a PE ratio of -7.00 and a beta of 0.72. The company has a 50-day moving average of $0.24 and a two-hundred day moving average of $0.29.
Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.01) earnings per share (EPS) for the quarter.
About Guided Therapeutics
Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.
The company secured 510(k) clearance from the U.S.
Featured Stories
- Five stocks we like better than Guided Therapeutics
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
- GE Aerospace Faces a Prove-It Moment in Q2 Earnings
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
